Frontlight ResearchEarly access
TerminatedPhase 2/3
Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
Key facts
- Who runs it
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Where
- Bangladesh, China, India, Indonesia, and Spain12 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2/3
- People taking part
- 369 people enrolled
- Started
- 23 Jul 2020
- Ended
- 26 Mar 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- BDB-001 Injection
- Conventional treatment
- Record updated
- 22 May 2024
- Why it stopped
- Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- 18 years old ≤ age ≤ 80 years old, both men or women
- Confirmed SARS-CoV-2 infection, and meet at least one of the following criteria:; Confirmed severe COVID-19 in no more than 5 days who meets any of the following criteria:; Respiratory distress, RR ≥ 30 times/min; Finger oxygen saturation (SpO2) ≤93% in resting state(room air); Arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ≤ 300 mmHg (1 mmHg = 0.133kpa) in supine position; Pulmonary imaging shows lesion progression > 50% within 24-48 hours; Symptoms,signs or chest imaging indicates ALI/ARDS
- Requiring a mask oxygen therapy,high-flow nasal cannula oxygen therapy(HFNC)
- The informed consent form signed
Who cannot take part
- Subjects on current treatment with a complement inhibitor such as eculizumab within 1 month before randomization
- A subject has used the following drugs within 2 weeks prior to screening procedures:; Calcineurin inhibitors (e.g., ciclosporin, tacrolimus, etc.); Proliferation inhibitors (e.g., everolimus, sirolimus, etc.); Anti-metabolic drugs (e.g., mycophenolate mofetil, mycophenolate, purine sulphate, etc.); Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF)/recombinant human granulocyte colony stimulating factor (rhG-CSF)
- Subjects already progressed into critically severe COVID-19 Critical severe standards refer to FDA guidelines,as shown in Appendix 4 or sepsis and sepsis shock
- Subjects with hypersensitivity history to any ingredient contained in the drug
- Concomitant with the following situation:severe lung disease such as chronic obstructive pulmonary disease (moderate to severe type), lung cancers, active tuberculosis; severe cardiovascular and cerebrovascular disease: unstable angina pectoris, myocardial infarction, postcardiac surgery, cardiac function ≥ grade 3 (NYHA Classification), or had undergone heart surgery within 6 months before randomization; severe liver diseases (e.g. Child-Pugh score ≥ grade C); severe kidney diseases, such as renal insufficiency (GFR ≤ 15 mL/min/1.73m\^2); immune deficiencies or immune-related diseases : including organ or bone marrow transplantation, some autoimmune diseases, IgG4-related diseases, allergic alveolitis, vasculitis; malignancies
- Subject who meets any of the following criteria will be excluded from the trial:
- Pregnant or lactating woman
- Subjects who have participated in other interventional clinical trials in the last 3 months or during this trial
- Any other circumstances that the investigator considers inappropriate for the participation in this study
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001 injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome. Patients will be randomized to two treatment arms (Arm A: Conventional treatment + BDB-001; Arm B: Conventional treatment alone).
The 2 groups in the trial
- Treatment groupTreatment being tested
Treatment: BDB-001 Injection
- Control groupTreatment being tested
Treatment: Conventional treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III
- Record updated
- 22 May 2024